Tecfidera becomes latest Bass target

Multiple sclerosis (MS) drug Tecfidera dimethyl fumarate from Biogen Inc. (NASDAQ:BIIB) is the newest target in a string of patent challenges from hedge fund manager Kyle Bass.

Coalition for Affordable Drugs V, an entity associated with Bass, filed an inter partes review (IPR) on Wednesday with the U.S. Patent and Trademark Office challenging U.S. Patent No. 8,759,393, which covers Tecfidera and expires in 2019. The '393 patent is one of seven Orange Book-listed patents covering Tecfidera. The drug's last patent, U.S. Patent No. 8,399,514, expires in 2028. ...